Source study found

Story checked

Could this flowering plant help people lose body fat? (opens in a new tab)

news-medical.net · 2026-10-19

Short answerEvidenceSource

Short answer

Mostly not supported

Mostly not supported.

The claims we could check match the study, but some claims were not covered by the evidence reviewed.

1 supported
6 not covered

Checked against the study summary. The full text wasn't available, so some details couldn't be settled either way.

Share this check

Follow the evidence trail

The story

Could this flowering plant help people lose body fat?

news-medical.net · 2026-10-19

The story’s checkable claims.

Read the original story

NewsLink checks it

Mostly not supported

The one claim we could check holds up. One of seven claims matches the study. This overall rating is based only on the claims we could check. Six claims the study doesn't address.

1 supported
6 not covered

Open claim evidence

The source study

Efficacy and Safety of Lythrum salicaria Extract on Body Fat Reduction in Adults with a BMI of 23–30 kg/m2: A Randomized, Double-Blind, Placebo-Controlled Trial

Nutrients · 2026

Open source record

Then inspect each claim

Evidence layer

Claim by claim

Each claim gets a verdict. Expand it to see the evidence directly below.

Reading mode

Scan verdicts. Open evidence only when needed.

Browse by verdict

7 claims in this story

Showing all 7 claimsChoose a verdict to focus the list.

Claim 1 of 7Not coveredA 12-week clinical trial found that adults taking Lythrum salicaria extract lost body fat while placebo recipients gained it, offering early evidence of a potential plant-based approach to weight management.View evidenceHide evidence

As stated12 weeks

Why this verdict

The abstract-level profile supports a 12-week randomized, double-blind, placebo-controlled trial in adults with BMI 23–30 kg/m2 and supports a between-group body-fat result favoring Lythrum salicaria extract. However, the specific headline framing that extract recipients lost body fat while placebo recipients gained it is not contained in the abstract-level profile, which reports the adjusted between-group difference rather than raw within-group directions. The plant-based weight-management interpretation is hedged as early/potential and is broadly consistent with the trial, but the headline includes detail not verifiable at this depth.

Study evidence

Twelve-week supplementation with Lythrum salicaria extract powder was associated with greater reduction in DXA-measured body fat mass compared with placebo.PP: −2.01 kg (95% CI −2.51 to −1.52), p < 0.001; ITT: −2.04 kg (95% CI −2.66 to −1.42), p < 0.001

“single-center, randomized, double-blind, placebo-controlled trial”

Claim 2 of 7Not coveredThe article says the study was a randomized, double-blind, placebo-controlled superiority trial conducted at Pusan National University Korean Medicine Hospital in adults aged 19–75 years with BMI 23–30 kg/m².View evidenceHide evidence

As stated12 weeks

Why this verdict

The profile supports the randomized, double-blind, placebo-controlled 12-week design and the adult population aged 19–75 years with BMI 23–30 kg/m2. It also supports that the study was single-center. But the abstract-level profile does not verify the wording 'superiority trial' or the named site, Pusan National University Korean Medicine Hospital.

Study evidence

“single-center, randomized, double-blind, placebo-controlled trial”

Claim 3 of 7Not coveredAfter 12 weeks, the extract group lost an average of 0.58 kg of body fat, while the placebo group gained 1.43 kg; the baseline-adjusted between-group difference was −2.01 kg, with similar results in the intention-to-treat analysis.View evidenceHide evidence

As stated0.58 kg lost vs 1.43 kg gained; difference −2.01 kg

Why this verdict

The profile supports the baseline-adjusted between-group body-fat difference in the per-protocol population: −2.01 kg, with a similar ITT result of −2.04 kg. However, the stated within-group changes—0.58 kg body-fat loss in the extract group and 1.43 kg gain in placebo—are not available in the abstract-level profile, so the full numerical claim cannot be verified at this depth.

Study evidence

“single-center, randomized, double-blind, placebo-controlled trial”

Claim 4 of 7Not coveredThe supplement was also associated with lower body weight, BMI, and body fat percentage, while waist-to-hip ratio and lean mass did not differ significantly between groups.View evidenceHide evidence

As stated12 weeks

Why this verdict

The profile supports exploratory secondary analyses favoring the extract for body weight, BMI, and body fat percentage. But the abstract-level profile does not report the waist-to-hip ratio or lean-mass null findings, nor does it provide quantitative details for the secondary outcomes. The claim is appropriately hedged as associated, but part of it is not verifiable from the supplied abstract-level evidence.

Study evidence

Exploratory secondary analyses favored L. salicaria extract over placebo for BMI.

“Anthropometric measures, other DXA outcomes, and blood markers were assessed as secondary endpoints.”

Claim 5 of 7Not coveredThe article says adiponectin increased in the extract group and decreased in the placebo group, but other metabolic and inflammatory markers were not significantly different; the secondary findings were described as exploratory.View evidenceHide evidence

Why this verdict

The profile supports that adiponectin was among exploratory secondary outcomes and that exploratory analyses favored the extract for adiponectin. It also supports the caveat that secondary findings were exploratory. However, the specific within-group direction—adiponectin increased in the extract group and decreased in placebo—and the statement that other metabolic and inflammatory markers were not significantly different are not reported in the abstract-level profile.

Study evidence

Exploratory secondary analyses favored L. salicaria extract over placebo for BMI.

“Anthropometric measures, other DXA outcomes, and blood markers were assessed as secondary endpoints.”

Claim 6 of 7Not coveredThe extract was generally well tolerated over 12 weeks, with seven mild adverse events across both groups and no serious adverse events reported.View evidenceHide evidence

As stated12 weeks

Why this verdict

The profile supports that no serious adverse events were reported during the 12-week trial. It does not verify the stated count of seven mild adverse events across both groups, severity grading, or the broader conclusion that the extract was generally well tolerated based on detailed AE reporting, because the abstract-level profile says detailed AE rates and severity information are not provided.

Study evidence

The trial abstract reports that no serious adverse events occurred during 12 weeks of daily L. salicaria extract supplementation.

“No serious adverse events occurred.”

Claim 7 of 7SupportedThe researchers emphasized that the reduction in body fat was modest and that larger, multicenter, longer-term studies are needed to confirm the findings and assess durability and safety.View evidenceHide evidence

Why this verdict

The profile supports the cautionary framing: the trial was modest in size, single-center, and only 12 weeks; the authors noted that larger and longer trials are needed to confirm findings and investigate mechanisms, and the profile limitations emphasize durability and longer-term safety uncertainty. The exact phrasing that the reduction was 'modest' is not separately quoted in the abstract profile, but the overall limitation-and-confirmation claim is consistent with the supplied evidence.

Study evidence

“single-center, randomized, double-blind, placebo-controlled trial”

Study evidence

Exploratory secondary analyses favored L. salicaria extract over placebo for BMI.

“Anthropometric measures, other DXA outcomes, and blood markers were assessed as secondary endpoints.”

Then look for missing context

Context layer

What the story left out

Important study details the story did not include.

Primary efficacy analysis emphasized the per-protocol population, with supporting ITT analyses; PP emphasis is a potential limitation if deviations or missingness differed by group.
The story mentions that ITT results were similar, but the supplied presentation does not mention that PP was the primary efficacy analysis set or flag the potential bias limitation associated with PP emphasis.
From randomized, double-blind, placebo-controlled trial

4 things the story did carry across

The paper’s central evidence is a single-center, randomized, double-blind, placebo-controlled 12-week human trial of 500 mg/day Lythrum salicaria extract versus placebo in adults with BMI 23–30 kg/m2.
Primary endpoint was DXA-measured body fat mass change from baseline to day 84, with baseline-adjusted comparisons favoring extract versus placebo in PP and ITT analyses.
Secondary outcomes, including body weight, BMI, body fat percentage, and adiponectin, were exploratory and lacked effect estimates or detailed statistical metrics in the abstract-level profile.
Important limitations include modest sample size, short 12-week follow-up, and single-center design, limiting durability, generalizability, and longer-term safety assessment.

Then read the study layer

Study layer

Study at a glance

Scan the study first. Expand only the parts you want to inspect.

Pieces of work

Evidence read

study summary

Lead result

human in vivo

1Lead resulthuman in vivoDetermine whether 12-week supplementation with Lythrum salicaria extract reduces DXA-measured body fat mass versus placebo in adults with BMI 23–30 kg/m2.randomized, double-blind, placebo-controlled trialExpand

In plain English

Randomized, double-blind, placebo-controlled single-center trial in adults with BMI 23–30 kg/m2 comparing 500 mg/day Lythrum salicaria extract powder (≈400 mg extract solids/day) versus placebo for 12 weeks. Primary endpoint was change in body fat mass from baseline to day 84 measured by DXA; primary efficacy analysis was per-protocol (PP) with supporting intention-to-treat (ITT) analyses. In the PP population (n=84) and ITT population, baseline-adjusted between-group comparisons favored extract versus placebo for DXA-measured body fat mass. No serious adverse events were reported. Results are from the abstract; full trial-report details (randomization sequence, allocation concealment, adherence, full adverse-event reporting, and statistical model) are not provided in the abstract.

Key findings

Twelve-week supplementation with Lythrum salicaria extract powder was associated with greater reduction in DXA-measured body fat mass compared with placebo.PP: −2.01 kg (95% CI −2.51 to −1.52), p < 0.001; ITT: −2.04 kg (95% CI −2.66 to −1.42), p < 0.001
Exploratory secondary analyses favored the extract for BMI, body weight, body fat percentage, and adiponectin.

“single-center, randomized, double-blind, placebo-controlled trial”

What this piece can’t prove

Single-center trial limits generalizability.
Modest sample size (90 randomized; PP n=84) and short follow-up (12 weeks) limit assessment of durability and safety.
Primary emphasis on per-protocol analysis could introduce bias if deviations differed by group; while ITT results are reported, full population and missing-data handling details are not provided.

2 further details could not be confirmed from the summary.

2human in vivoAssess broader efficacy signals of L. salicaria extract on anthropometrics, other DXA body composition outcomes, and selected blood biomarkers (e.g., adiponectin).Randomized, double-blind, placebo-controlled trial (12 weeks)Expand

In plain English

In a single-center, randomized, double-blind, placebo-controlled 12-week trial of Lythrum salicaria extract (500 mg/day, ≈400 mg/day extract solids) versus placebo in adults with BMI 23–30 kg/m2 (N=90), exploratory secondary analyses reported that the extract favored improvements in anthropometrics (BMI, body weight), a DXA-derived metric (body fat percentage), and the blood biomarker adiponectin. The abstract does not report effect estimates or statistical details for these secondary outcomes; they were labeled as exploratory secondary endpoints assessed in the same trial.

Key findings

Exploratory secondary analyses favored L. salicaria extract over placebo for BMI.
Exploratory secondary analyses favored L. salicaria extract over placebo for body weight.

“Anthropometric measures, other DXA outcomes, and blood markers were assessed as secondary endpoints.”

What this piece can’t prove

The abstract does not present effect sizes, confidence intervals, or p-values for the secondary outcomes, limiting quantitative appraisal.
Single-center trial with modest sample size (N=90 randomized; PP n=84) and short duration (12 weeks).
Findings for these secondary endpoints are reported within the same trial and require confirmation in larger and longer studies.

1 further detail could not be confirmed from the summary.

3human in vivoEvaluate safety/tolerability of daily L. salicaria extract over 12 weeks, including adverse events and safety labs/vitals as collected in the trial.Randomized, double-blind, placebo-controlled trial (12 weeks)Expand

In plain English

Within a 12-week randomized, double-blind, placebo-controlled trial of Lythrum salicaria extract (500 mg/day) versus placebo in adults with BMI 23–30 kg/m2 (n=90 randomized; per-protocol n=84), the abstract reports safety outcomes stating that no serious adverse events occurred. The trial included adverse-event surveillance and clinical assessments (blood markers reported as secondary endpoints), but the abstract provides no numerical AE rates, severity grading, or detailed laboratory/vital-sign results.

Key findings

The trial abstract reports that no serious adverse events occurred during 12 weeks of daily L. salicaria extract supplementation.

“No serious adverse events occurred.”

What this piece can’t prove

Short follow-up (12 weeks) and modest sample size reduce ability to detect rare or long-term harms.
Single-center design may limit generalizability of safety findings.
Unclear whether all randomized participants were included in safety analyses or how missing/withdrawn participants were handled for harms reporting.

1 further detail could not be confirmed from the summary.

Finally, the search trail

Method layer